Critical reviews in oncology/hematology · 2020
First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings.
СтатьяСистематический обзорNetwork Meta-AnalysisНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ferro Matteo, Lucarelli Giuseppe, Crocetto Felice, Dolce Pasquale, Verde Antonio, La Civita Evelina, Zappavigna Silvia, de Cobelli Ottavio, Di Lorenzo Giuseppe, Facchini Bianca Arianna, Scafuri Luca, Onofrio Livia, Porreca Angelo, Busetto Gian Maria, Sonpavde Guru, Caraglia Michele, Klain Michele, Terracciano Daniela, De Placido Sabino, Buonerba Carlo
Аннотация
Although both docetaxel and androgen-receptor-axis-targeted (ARAT) agents have yielded survival improvements in combination with androgen deprivation therapy (ADT) compared to ADT alone in metastatic castration-sensitive prostate cancer (mCSPC) patients, the optimal therapeutic choice remains to be established. We analyzed estimates of the hazard ratios for death (OS-HRs) in patients treated in the first-line setting enrolled in the GETUG-AFU15, CHAARTED, STAMPEDE, LATITUDE, ENZAMET, and TITAN trials. Overall, men with mCSPC receiving ADT with vs. without either an ARAT agent or docetaxel as first-line systemic therapy showed a pooled OS-HR of 0.69 (95 % CI: 0.61-0.78), with significant heterogeneity (p = 0.045, I2 = 52.5 %). Network meta-analysis showed an OS-HR in patients receiving an ARAT agent vs. docetaxel of 0.78 (95 %CI: 0.67-0.91). In conclusion, the evidence analysed indicates that an ARAT agent may provide improved OS outcomes compared to docetaxel. Prospective randomized trials are warranted.